Drug-Induced Lupus Erythematosus (DILE): A Comprehensive Analysis of Pathogenesis, Clinical Profiles, Diagnosis, and Management Strategies
DOI:
https://doi.org/10.33974/cj6cc178
Keywords:
Autoimmune Disorders, ADR, Anti-histone Antibodies, Drug Withdrawal Drug-Induced Lupus Erythematosus (DILE), Systemic Lupus Erythematosus (SLE)Abstract
Drug-induced lupus erythematosus (DILE) represents a distinctive autoimmune phenomenon characterized by its association with prolonged exposure to certain medications, as opposed to the idiopathic nature of systemic lupus erythematosus (SLE). Unlike SLE, the hallmark feature of DILE is its tendency to remit upon cessation of the offending drug. This article embarks on a comprehensive exploration of DILE, elucidating its pathogenesis, clinical presentations, diagnostic criteria, and therapeutic interventions through a meticulous analysis of contemporary scholarly works. The pathogenesis of DILE is multifaceted, involving complex interactions between genetic predisposition, immune dysregulation, and the pharmacological properties of implicated medications. Understanding these intricate mechanisms is pivotal in both diagnosis and management. Clinical manifestations of DILE often mirror those of SLE, encompassing a spectrum of symptoms ranging from constitutional complaints to organ-specific involvement. Navigating the diagnostic landscape of DILE necessitates a discerning approach, leveraging a combination of clinical assessment, laboratory investigations, and exclusionary criteria to differentiate it from other autoimmune entities, particularly SLE. Management of DILE hinges upon prompt recognition and withdrawal of the offending agent, which typically precipitates clinical improvement and eventual resolution of symptoms. Pharmacological interventions may be warranted to alleviate acute manifestations or mitigate disease progression in refractory cases. However, the efficacy and safety profile of such treatments warrant careful consideration in light of potential adverse effects and drug interactions.
Downloads
References
Engavale MB. Determining the impact of macro-phage-derived Dnase1L3 in lupus-like phenotypes in mice and its implications for treatment [thesis]. 2023. No DOI.
Batu ED, Ozen S. Classification of pediatric vascu-litides. In: The vasculitides. Vol. 145. No DOI.
Chan JC. Clinical disorders of the kidney. Pediatr Clin North Am. 2018;66(1). https://doi.org/10.1016/j.pcl.2018.08.002
Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009;301:99–105. https://doi.org/10.1007/s00403-008-0895-5
Sarzi-Puttini P, Atzeni F, Capsoni F, et al. Drug-induced lupus erythematosus. Autoimmunity. 2005;38(7). https://doi.org/10.1080/08916930500285754
Antonov D, Kazandjieva J, Etugov D, et al. Drug-induced lupus erythematosus. Clin Dermatol. 2004;22(2):157–166. https://doi.org/10.1016/j.clindermatol.2003.12.009
Kaya Akca U, et al. Drug-induced lupus erythemato-sus in childhood: case-based review. Lupus. 2024. https://doi.org/10.1177/09612033241245078
Murphy G. Drug-induced lupus. In: Dubois' lupus erythematosus and related syndromes. 2025. p. 402–412. No DOI.
Nguyen T, et al. Drug-induced lupus following mRNA COVID-19 vaccination and monoclonal antibody in-fusion. Kans J Med. 2024;17:36. https://doi.org/10.17161/kjm.vol17.18960
Amrhein JA, Kenny FM, Ross D. Granulocytopenia, lupus-like syndrome, and other complications of propylthiouracil therapy. J Pediatr. 1970;76(1):54–63. No DOI.
Beernink DH, Miller JJ. Anticonvulsant-induced anti-nuclear antibodies and lupus-like disease in children. J Pediatr. 1973;82(1):113–117. No DOI.
Irias JJ. Hydralazine-induced lupus erythematosus-like syndrome. Am J Dis Child. 1975;129(7):862–864. No DOI.
Singsen BH, Fishman L, Hanson V. Antinuclear anti-bodies and lupus-like syndromes in children receiv-ing anticonvulsants. Pediatrics. 1976;57(4):529–534. No DOI.
Vanheule B, Carswell F. Sulphasalazine-induced sys-temic lupus erythematosus in a child. Eur J Pediatr. 1983;140(1):66–68. No DOI.
Oner A, Topaloglu R, Besbas N, et al. Carbamazepine induced systemic lupus erythematosus. Clin Neurol Neurosurg. 1990;92(3):261–262. https://doi.org/10.1016/0303-8467(90)90090-7
Tolaymat A, Leventhal B, Sakarcan A, et al. Systemic lupus erythematosus in a child receiving long-term interferon therapy. J Pediatr. 1992;120(3):429–432. https://doi.org/10.1016/S0022-3476(05)80998-4
Kanno T, Miyata M, Kazuta Y, et al. Carbamazepine-induced systemic lupus erythematosus-like disease. Intern Med. 1992;31(11):1303–1305. https://doi.org/10.2169/internalmedicine.31.1303
Ansell BM. Drug-induced systemic lupus erythema-tosus in a nine-year-old boy. Lupus. 1993;2(3):193–194. https://doi.org/10.1177/096120339300200311
Sato-Matsumura KC, Koizumi H, Matsumura T, et al. Lupus erythematosus-like syndrome induced by thi-amazole and propylthiouracil. J Dermatol. 1994;21(7):501–507. https://doi.org/10.1111/j.1346-8138.1994.tb01785.x
Quilty B, McHugh N. Lupus-like syndrome associated with the use of minocycline. Br J Rheumatol. 1994;33(12):1197–1198. https://doi.org/10.1093/rheumatology/33.12.1197
Riviello JJ, Raphael SA, Brown LW, et al. Ethosuximide-associated systemic lupus erythemato-sus in childhood. J Epilepsy. 1994;7(1):23–26. No DOI.
Byrne P, Williams B, Pritchard M. Minocycline-related lupus. Br J Rheumatol. 1994;33(7):674–676. https://doi.org/10.1093/rheumatology/33.7.674
Gendi N, Bowman S, Mowat A. Lupus-like syndrome in patients treated for acne. Br J Rheumatol. 1995;34(6):584–585. https://doi.org/10.1093/rheumatology/34.6.584
Tellez Arevalo AM, et al. Synthetic pharmacotherapy for systemic lupus erythematosus. Medicina (Kau-nas). 2022;59(1):56. https://doi.org/10.3390/medicina59010056
Sim TM, Mak A, Tay SH. Insights into the role of neu-trophils in neuropsychiatric SLE. Front Immunol. 2022;13:957303. https://doi.org/10.3389/fimmu.2022.957303
Izmirly PM, Kim MY, Llanos C, et al. Risk of anti-SSA/Ro-SSB/La antibodies in neonatal lupus. Ann Rheum Dis. 2010;69:1827–1830. https://doi.org/10.1136/ard.2009.119263
Kumar DM, Kamath L, Reddy N. Efficacy of hy-droxychloroquine as antidiabetic drug. Int J Basic Clin Pharmacol. 2017;6:895. https://doi.org/10.18203/2319-2003.ijbcp20171325
Hage MP, Al-Badri MR, Azar ST. Effect of hy-droxychloroquine on glucose and lipid metabolism. Ther Adv Endocrinol Metab. 2014;5:77–85. https://doi.org/10.1177/2042018814525695
Capell HA. Effect of antimalarial agents on lipid pro-file in SLE. J Rheumatol. 2001;28:1742. No DOI.
Stapley L. Bone loss prevention by an antimalarial drug. Trends Endocrinol Metab. 2001;12:146. https://doi.org/10.1016/S1043-2760(01)00400-4
Ruiz-Irastorza G, Ugarte A, Egurbide MV, et al. Anti-malarials may influence malignancy risk in SLE. Ann Rheum Dis. 2007;66:815–817. https://doi.org/10.1136/ard.2006.065524
Abdel Galil SM. Hydroxychloroquine-induced toxic hepatitis. Lupus. 2015;24:638–640. https://doi.org/10.1177/0961203314560208
Jimenez-Alonso J, Tercedor J, Jaimez L, et al. Antima-larial drug-induced pruritus in lupus. Arthritis Rheum. 1998;41:744–745. https://doi.org/10.1002/1529-0131(199804)41:4<744::AID-ART22>3.0.CO;2-8
Marriott P, Borrie PF. Pigmentary changes following chloroquine. J R Soc Med. 1975;68:535–536. No DOI.
Pasero G, Marson P. Corticosteroid therapy history. Reumatismo. 2011;62:292–299. https://doi.org/10.4081/reumatismo.2011.292
Benedek TG. Development of corticosteroid therapy. Clin Exp Rheumatol. 2011;29:5–12. No DOI.
Compston J. Glucocorticoid-induced osteoporosis. Endocrine. 2018;61:7–16. https://doi.org/10.1007/s12020-018-1588-2
Stojan G, Petri M. Risk-benefit of glucocorticoids in SLE. Curr Treat Options Rheumatol. 2017;3:164–172. https://doi.org/10.1007/s40674-017-0069-8
Biddie SC, Conway-Campbell BL, Lightman SL. Regu-lation of glucocorticoid signalling. Rheumatology. 2012;51:403–412. https://doi.org/10.1093/rheumatology/ker215
Surjit M, Ganti KP, Mukherji A, et al. Glucocorticoid receptor repression mechanisms. Cell. 2011;145:224–241. https://doi.org/10.1016/j.cell.2011.03.027
Buttgereit F, Saag KG, Cutolo M, et al. Molecular basis of glucocorticoid action. Scand J Rheumatol. 2005;34:14–21. https://doi.org/10.1080/03009740510018648
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Robin George, Abhishek Thiruganahalli Suresh, Harshitha Mavinahalli Ramnath, Ellampati Sunil Kumar (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
License Terms
This is an open-access article published in the International Journal of Research in Pharmaceutical Sciences and Technology (IJRPST) by Rubatosis Publications.
It is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, reproduction, and adaptation in any medium or format, provided the original author(s) and source are appropriately credited, a link to the license is provided, and any changes made are indicated.
To view a copy of this license, visit: https://creativecommons.org/licenses/by/4.0/
For any further queries or permissions beyond the scope of this license, please contact: editor@rubatosis.org
